Wednesday, 04 January 2023

STI 2023 YEAR-END TARGET: 3,520

STRATEGY - SINGAPORE

1H23 Market Strategy

A Safe Harbour In A Stormy Sea

While the China reopening story may see a short-term bullish reaction in the market, we believe that recessionary risks persist nonetheless. For 2023, we forecast 6% EPS growth for the large-cap stocks under our coverage, and from a top-down basis, our 2023 year-end target of 3,520 for the STI implies 8% upside from current levels. Importantly, the index's valuations are not stretched at present, trading at 2023F PE and P/B of 10.7x and 1.0x respectively, and paying a yield of 4.5%.

WHAT'S NEW?

- Staying constructive for 1H23. While the post-COVID-19 global economic recovery has been bumpy, with concerns such as inflation and higher interest rates dominating the market's attention, the Straits Times Index (STI) nevertheless managed a total return of 6.6% in 2022. In our view, this outperformance should continue due to the defensive nature of the STI given the prevalence of quality, value and dividend stocks relative to its regional peers. Since there will no longer be a synchronous global cycle, country risk will return and our view is that Singapore presents a lower risk vs other countries in the region.
- 6% EPS growth for 2023. We forecast an aggregate 6% EPS growth in 2023 for the Singapore market with the aviation, financial, and telecommunications sectors leading the way, followed by the consumer and gaming sectors. Somewhat offsetting this are the healthcare, land transport, plantation, property and REITs sectors which are expected to show earnings declines in 2023.
- We forecast the STI to reach 3,520 by end-23 using a top-down methodology, implying about 8% upside from current levels. Our 2023 STI target is based on 6% earnings growth for 2023, and target PE and P/B of 12.9x and 1.3x respectively, both of which are at about a 15% discount to the index's long-term average. We believe this is fair given moderating earnings growth and potential recessionary risks to the economy and thus our forecasts.
- 2023 valuations for the STI appear inexpensive, with the STI trading at a forecast 2023 PE and P/B of 10.8x and 1.0x respectively, and paying a yield of 4.9%. We highlight that these multiples are meaningful discounts to the STI's long-term averages.
- A tough year for Singapore in 2023. UOB GEMR forecasts Singapore GDP growth of 0.7% yoy in 2023 after the reasonably solid 3.5% growth in 2022. Near-term non-oil domestic export data and PMIs have been weak with the export and manufacturing sectors negatively impacted by slowing demand from China and the US.
- Our top large-cap picks are CapitaLand Ascott Trust, CapitaLand Investment, DBS Group, Genting Singapore, Keppel Corp, Mapletree Logistics Trust, Sembcorp Industries, Singapore Telecommunications, SIA Engineering, Thai Beverage, Venture Corp and Wilmar International.


Click here for Blue Top dated 03 Jan 23

SECTOR PICKS

Company	Rec	Price	Price (S\$)			
		30 Dec	Target			
CapitaLandInvest	BUY	3.70	4.13			
CapLand Ascott T	BUY	1.05	1.27			
DBS	BUY	33.92	45			
Genting SP	BUY	0.955	1.08			
Keppel Corp	BUY	7.26	10.11			
MapletreeLog	BUY	1.59	1.87			
OCBC	BUY	12.18	18.28			
Sembcorp Ind	BUY	3.38	4.1			
SIA Engineering	BUY	2.34	2.60			
Singtel	BUY	2.57	3.15			
Venture Corp	BUY	17.06	20.06			
Wilmar	BUY	4.17	5.50			
Small caps						
Civmec	BUY	0.575	1.18			
Food Empire	BUY	0.635	0.78			
UMS	BUY	1.18	1.38			

Source: Bloomberg, UOB Kay Hian

STI PERFORMANCE VS REGIONAL PEERS



Straits Jakarta Hang Seng Kuala Stock MSCI Asia Times Index Compositve Index Lumpur Exchange of ex Japan Composite Thailand Index

Source: Bloomberg

ANALYST(S)

Adrian Loh +65 6590 6633 adrianloh@uobkayhian.com

Singapore Research Team +65 6535 6868 Research@uobkayhian.com

PEER COMPARISON

Company	Ticker	Rec	Price	e (S\$)	Upside to		PE (x)		2023	F (%)	M.cap	P/B
			30 Dec	Target	TP (%)	2022F	2023F	2024F	Yield	ROE	S\$m	(x)
CapitaLandInvest	CLI SP	BUY	3.70	4.13	11.6	11.2	10.5	9.5	2.4	7.7	18,922.4	1.2
CapLand Ascott T	CLAS SP	BUY	1.05	1.27	21.0	37.0	23.9	22.0	5.9	3.5	3,617.9	0.9
DBS	DBS SP	BUY	33.92	45.0	32.7	11.1	9.5	8.8	5.2	15.3	87,298.6	1.6
Genting SP	GENS SP	BUY	0.955	1.08	13.1	32.1	16.6	16.1	3.7	8.6	11,528.8	1.5
Keppel Corp	KEP SP	BUY	7.26	10.11	39.3	15.5	14.4	13.1	2.8	7.2	12,719.2	1.1
MapletreeLog	MLT SP	BUY	1.59	1.87	17.6	18.7	20.6	20.6	5.5	4.9	7,647.1	1.1
OCBC	OCBC SP	BUY	12.18	18.28	50.1	9.2	8.2	7.8	4.9	11.8	54,747.2	1.1
Sembcorp Ind	SCI SP	BUY	3.38	4.10	21.3	8.4	11.4	11.0	2.7	12.1	6,005.2	1.4
SIA Engineering	SIE SP	BUY	2.34	2.60	11.1	31.4	20.2	15.2	3.8	7.6	2,626.8	1.6
Singtel	ST SP	BUY	2.57	3.15	22.6	17.5	16.2	15.0	4.9	9.1	42,415.6	1.6
Venture Corp	VMS SP	BUY	17.06	20.06	17.6	13.6	13.0	12.0	4.7	13.0	4,964.5	1.8
Wilmar	WIL SP	BUY	4.17	5.50	31.9	8.9	10.8	9.2	4.9	8.6	26,031.1	0.9

Source: Bloomberg, UOB Kay Hian



Wednesday, 04 January 2023

- A more uncertain 2023 after a firm 2022. While improved fundamentals have allowed ASEAN markets to withstand the financial market volatility in 2022, the year ahead is expected to remain uncertain and challenging amid looming risks with economic recessions in the US and Europe, tightening financial conditions, further straining of US-China relations and the Russia-Ukraine conflict, among others. In particular, for an open economy like Singapore's, the possibility of spillovers from these risk factors cannot be ignored.
- STI performed strongly in 2022. Our call to remain invested in the Singapore market at the beginning of 2022, which we reiterated at the start of 2H22, proved to be correct, with the STI's total return of 6.6% ytd outperforming all of its peers (see chart on RHS). Given the defensive characteristics of the Singapore market, we believe that investors should remain invested. We highlight that we are forecasting 6% yoy EPS growth for 2023 within our UOB Kay Hian coverage universe. As a result, our top-down forecast for the STI for end-22 is 3,520, implying an upside of around 8% from current levels.
- Singapore has recovered well. The above risks are somewhat offset by the ongoing recovery in domestic activities, the relaxation of COVID-19 pandemic restrictions and reopening of cross border movements, which will benefit domestic-oriented sectors such as retail, food & beverage, transport and accommodation, among others. We have already seen the positive effect of this on the aviation sector and with China now reopening its borders, Singapore's tourism sector should be well-placed to benefit from this.
- We believe that the Singapore market will outperform due to the prevalence of quality, value and dividend stocks relative to its regional peers. Since there will no longer be a synchronous global cycle, country risk will return and our view is that Singapore presents a lower risk vs other countries in the region, especially given the defensive nature of a number of its listed companies. The clear risk for the market is a global recession which, given Singapore's open economy, would negatively affect it.
- Forecasting 6% earnings growth in 2023. The four key sectors that will contribute to the positive earnings growth in 2023 are the aviation, financials, telecommunications and "others" sectors (see table below), with aviation coming off a low base in 2022. We expect the healthcare, land transport, property and plantation sectors to be four key sectors that will degrade the positive earnings growth, with the latter sector to be negatively impacted by weaker CPO prices. Note that the property sector's EPS decline is due to City Development's extraordinary gain from the sale of its Millenium Hilton in Seoul that will be recognised in 2022.


CORE EPS GROWTH BY SECTOR (% CHANGE YOY)

	2020	2021	2022E	2023E	2024E
Aviation	n.a.	n.a.	n.a.	18.7	(44.0)
Finance	(29.6)	38.9	19.1	15.6	7.5
Healthcare	11.8	26.0	58.3	(8.4)	(7.2)
Land Transport	(62.4)	18.2	50.0	(4.6)	9.1
Plantation	21.5	28.7	26.3	(20.4)	13.4
Property	n.a.	n.a.	78.3	(31.6)	4.6
REITs	(20.3)	26.9	4.7	(2.7)	1.1
Shipyard	n.a.	n.a.	34.8	2.0	10.2
Technology	(18.4)	4.6	16.6	4.4	9.1
Telecommunications	(58.1)	94.0	18.2	8.6	8.4
Others*	(36.8)	9.9	21.2	16.7	8.1
AGGREGATE GROWTH	(66.9)	137.8	22.6	5.6	3.2

Note: Others comprise of Singpost, DFI Retail Group, Thai Beverage and Genting Singapore Source: UOB Kay Hian

• Playing the laggards. For those playing the laggard theme, stocks that could see a rebound in 1H23 include SATS, Starhub and ST Engineering; we have left out any REITs from this shortlist as it appears that the US Fed will likely continue raising rates in the near term. We note that in 2H22, three of the five laggards that we highlighted – DBS, SMM, and Genting Singapore – outperformed the STI by an average of 18.3ppt.

BEST PERFORMING STOCKS IN 2022



Source: Bloomberg


SINGAPORE PMI



Source: Bloomberg


Wednesday, 04 January 2023

REGIONAL MARKETS' 12-MONTH FORWARD PE



Note: Historical range represents 10th to 90th percentile from 2007 to present Source: Bloomberg

CONSUMER PRICE INDEX - % CHANGE YOY



Source: Bloomberg

STI VS CONSUMER PRICE INDEX



Source: Bloomberg

STRAITS TIMES INDEX: LONG TERM PE CHART




Source: Bloomberg

DOWNWARD REVISION TO CONSENSUS GDP GROWTH FORECASTS



Source: Bloomberg

QOQ % CHANGE - STI VS SINGAPORE GDP



Note: Shaded areas represent recessions

Source: Bloomberg



Wednesday, 04 January 2023

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.



Wednesday, 04 January 2023

Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

ollowing lable	
General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or
	located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to
	applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the
	Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has
	trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed
	corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under
	Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong
	Kong and contains research analyses or reports from a foreign research house, please note:
	(i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong
	Kong in respect of any matters arising from, or in connection with, the analysis or report; and
	(ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong
	who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the
	analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority
	of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a
	foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant
	foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the
	recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia,
	at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the
	registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital
	markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the
	report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note:
	(i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore
	in respect of any matters arising from, or in connection with, the analysis or report; and
	(ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore
	who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the
T	contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated
11.76	by the Securities and Exchange Commission of Thailand.
United	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning
Kingdom	of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in
11.20	the UK is intended only for institutional clients.
United	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S.
States of	laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its
America	contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in
('U.S.')	the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2023, UOB Kay Hian Pte Ltd. All rights reserved.

http://research.uobkayhian.com

RCB Regn. No. 197000447W